Pharmacologic Inhibition by Grapefruit Juice
Grapefruit juice primarily inhibits intestinal cytochrome P450 3A4 (CYP3A4) and organic anion-transporting polypeptide 1A2 (OATP1A2), with potential effects on P-glycoprotein (P-gp) transport. 1
Primary Enzyme and Transporter Targets
CYP3A4 Inhibition
Grapefruit juice produces mechanism-based inhibition of intestinal CYP3A4, which increases oral bioavailability of drugs that are CYP3A4 substrates and undergo significant first-pass metabolism 1. The active constituents responsible for this inhibition are furanocoumarins, particularly bergamottin and 6',7'-dihydroxybergamottin, along with flavonoids including naringin, naringenin, hesperidin, and hesperetin 1, 2.
This inhibition is irreversible and mechanism-based, meaning the effect persists beyond the immediate presence of grapefruit juice in the gastrointestinal tract. The clinical impact can last more than 2 hours but less than 4 hours after consumption 3.
OATP1A2 Inhibition
Grapefruit juice potently inhibits OATP1A2, an uptake transporter located on the brush border of enterocytes 3, 4. This represents a bidirectional effect: while CYP3A4 inhibition increases drug bioavailability, OATP1A2 inhibition decreases oral bioavailability of drugs requiring this transporter for intestinal absorption 5, 3, 2.
Key affected drugs via OATP1A2 inhibition include:
- Fexofenadine (bioavailability reduced by 50% with normal juice amounts) 3, 4
- Acebutolol
- Celiprolol
- Talinolol
- L-thyroxine 3
P-glycoprotein Effects
Grapefruit juice may inhibit intestinal P-glycoprotein-mediated efflux transport, though this effect is less clinically significant than CYP3A4 inhibition 2. The clinical relevance depends on whether the drug has high inherent oral bioavailability—for example, grapefruit juice increases cyclosporine absorption but does not enhance digoxin absorption 2.
Clinical Implications by Drug Class
Drugs with Increased Bioavailability (via CYP3A4 inhibition):
- Immunosuppressants: Ciclosporin levels can increase significantly; complete avoidance of grapefruit juice is recommended 6
- Tyrosine kinase inhibitors: Nilotinib and dasatinib plasma concentrations increase; grapefruit juice should be avoided 7
- Statins: Marked increases in serum levels with increased rhabdomyolysis risk 6
Drugs with Decreased Bioavailability (via OATP1A2 inhibition):
- Antihistamines (fexofenadine)
- Beta-blockers (acebutolol, celiprolol, talinolol)
- Thyroid hormone replacement 3
Volume-Effect Relationship
The magnitude of interaction is dose-dependent. Normal juice amounts (approximately 200-240 mL/day) can produce clinically significant effects 8, 3. Even a single glass can halve fexofenadine absorption 3. For patients on warfarin who prefer grapefruit juice, consumption should not exceed 200 mL/day 8.
Important Caveats
The interaction is not immediately contraindicated for all drug combinations. Consider: 1
- The amount and type of juice being consumed
- Whether the drug has low inherent bioavailability
- Specific characteristics of the documented interaction
- Individual patient variability in transporter and enzyme expression
Timing strategies are insufficient: Because CYP3A4 inhibition is mechanism-based and long-lasting, simply separating grapefruit juice and medication administration does not reliably prevent the interaction 6, 3. Complete avoidance is the safest approach for drugs with narrow therapeutic indices or significant CYP3A4 metabolism.